



Uceris® (budesonide) – First-time generic

- On July 9, 2018, [Teva launched](#) an [AB-rated](#) generic version of Salix Pharmaceuticals' [Uceris \(budesonide\)](#) extended-release tablets.
- Uceris is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
- Budesonide is also available generically as an [oral capsule](#), a [nasal spray](#), and a [nebulizer suspension for inhalation](#).
 - The oral capsule is approved for the treatment and maintenance of clinical remission of Crohn's disease.
 - The nasal spray is approved for the treatment of seasonal or perennial allergic rhinitis.
 - The nebulized solution for inhalation is approved for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
- Additional branded products containing budesonide include [Uceris rectal foam](#), [Pulmicort Flexhaler™](#), and [Symbicort®](#). Symbicort also contains formoterol.
 - Uceris rectal foam is approved for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 centimeters from the anal verge.
 - Pulmicort Flexhaler is approved for the maintenance treatment of asthma.
 - Symbicort is approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Symbicort 160/4.5 is also indicated to reduce exacerbations of COPD.
- Uceris had annual sales of approximately \$196 million in the U.S., according to IMS data as of May 2018.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.